Thoraflex Hybrid
Vascutek, Ltd. · Decision date Jan 29, 2026
What did the FDA approve?
FDA records P210006/S016 as a supplement to PMA P210006, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jan 29, 2026.
FDA approval order statement
an update to the lFU to include additional language regarding early imaging surveillance for patients at risk for intraluminal thrombosis
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 29, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P210006/S016
- Regulatory pathway
- PMA supplement
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- Decision code
- APPR
- Decision date
- Jan 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hybrid stent graft, thoracic aortic lesion treatment.
- Applicant
- Vascutek, Ltd.
- Product code
- QSK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210006. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210006 · Original PMA
Thoraflex Hybrid
P210006/S013 · Related supplement
Thoraflex Hybrid
P210006/S014 · Related supplement
Thoraflex Hybrid
P210006/S015 · Related supplement
Thoraflex Hybrid
P210006/S016 received
Application receipt date recorded by FDA.
P210006/S016 · FDA decision
Special (Immediate Track)
P210006/S017 · Related supplement
Thoraflex Hybrid
P210006/S019 · Related supplement
Thoraflex Hybrid
P210006/S018 · Related supplement
Thoraflex Hybrid
Timeline entries are records held by MedtechLedger for P210006. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210006
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Thoraflex HybridP210006 | Vascutek, Ltd. | PMA approval | Apr 19, 2022 | FDA |
Thoraflex HybridP210006/S013 | Vascutek, Ltd. | PMA supplement | Jul 30, 2025 | FDA |
Thoraflex HybridP210006/S014 | Vascutek, Ltd. | PMA supplement | Oct 16, 2025 | FDA |
Thoraflex HybridP210006/S015 | Vascutek, Ltd. | PMA supplement | Oct 29, 2025 | FDA |
Thoraflex HybridP210006/S017 | Vascutek, Ltd. | PMA supplement | Apr 20, 2026 | FDA |
Thoraflex HybridP210006/S019 | Vascutek, Ltd. | PMA supplement | Jun 24, 2026 | FDA |
Thoraflex HybridP210006/S018 | Vascutek, Ltd. | PMA supplement | Sep 8, 2026 | FDA |
Explore the linked device profile
Other records with product code QSK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AMDS Hybrid ProsthesisP250055 | Artivion, Inc | PMA approval | Jun 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vascutek, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Newmains Ave., Inchinnan, PA49RR
Sources and methodology
- Original FDA record: P210006/S016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




